Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368825 | 0.87 | EPHX2 (0.59) | SCDEPHX2CYP2C9EGLN1KDM4E | |
| SCHEMBL6346657 | 0.86 | SCD (0.56) | SCDEPHX2CYP2C9CYP2J2GRIN2B | |
| SCHEMBL6354166 | 0.82 | EPHX2 (0.57) | SCDEPHX2NAMPT | |
| SCHEMBL6345619 | 0.82 | SCD (0.52) | SCDEGLN1KDM4EALDH1A1HTT | |
| SCHEMBL6355548 | 0.80 | CYP2D6 (0.48) | SCDEPHX2CYP2C9EGLN1KDM4E | |
| SCHEMBL6421169 | 0.80 | GRIN2B (0.66) | CYP2C9EGLN1KDM4EALDH1A1HTT | |
| SCHEMBL6346087 | 0.80 | SCD (0.51) | SCDEPHX2CYP2C9CYP2J2L3MBTL1 | |
| SCHEMBL2637558 | 0.79 | EPHX2 (0.52) | SCDEPHX2CYP2C9CYP2J2MAPT | |
| SCHEMBL4577340 | 0.79 | SCD (0.56) | SCDEPHX2KDM4EALDH1A1HTT | |
| SCHEMBL639198 | 0.79 | EPHX2 (0.60) | EPHX2CYP2C9CYP2J2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | SCD 343/4885EPHX2 1259/4885CYP2C9 2462/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | SCD 551/4885EPHX2 1576/4885CYP2C9 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.